The effect of enoxaparin on bleomycin-induced lung injury in mice

Experimental Lung Research

Volumn 25, Issue 6, 1999, Pages 531-541

  Laxer, U ^a   Lossos, I S ^b   Gillis, S ^b   Or, R ^c   Christensen, T G ^d   Goldstein, R H ^d   Breuer, Raphael ^a,b,d  

^a HEBREW UNIVERSITY   (Israel)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^c HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^d BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bleomycin; Enoxaparin; Interstitial lung disease; Low molecular weight heparin; Mice

Indexed keywords

ANTICOAGULANT AGENT; BLEOMYCIN SULFATE; ENOXAPARIN; LOW MOLECULAR WEIGHT HEPARIN; PROCOAGULANT; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; IMAGE ANALYSIS; INTRAPERITONEAL DRUG ADMINISTRATION; INTRATRACHEAL DRUG ADMINISTRATION; LUNG ALVEOLUS WALL; LUNG FIBROSIS; LUNG INJURY; LUNG LAVAGE; MOUSE; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL;

ANIMALS; ANTICOAGULANTS; BLEOMYCIN; BRONCHOALVEOLAR LAVAGE FLUID; CELL COUNT; ENOXAPARIN; FACTOR XA; FEMALE; IMAGE PROCESSING, COMPUTER-ASSISTED; INJECTIONS, INTRAPERITONEAL; LUNG; LUNG DISEASES, INTERSTITIAL; MICE; MICE, INBRED C57BL;

EID: 0032848335     PISSN: 01902148     EISSN: None     Source Type: Journal    
DOI: 10.1080/019021499270114     Document Type: Article

References (33)

1. Piguct PF: Cytokines involved in pulmonary fibrosis. Int Rev Exp Pathol. 1993;34b:173-181.
2. Snider GL, Celli BR, Goldstein RH, O'Brien JJ, Lucey EC: Chronic interstitial pulmonary fibrosis produced in hamsters by endotrachcal bleomycin. Am Rev Respir Dis. 1978;117:289-297.
3. Chandler DB, Hyde DM, Giri SN: Morphometric estimates of infiltrative cellular changes during the development of bleomycin-induced pulmonary fibrosis in hamsters. Am J Pathol. 1983;112:170-177.
4. Chapman HA, Allen CL, Stone OL: Abnormalities in pathways of alveolar fibrin turnover among patients with interstitial lung disease. Am Rev Respir Dis. 1986;133:433-437.
5. Chapman HA, Stahl M, Allen CL, Yee R, Fair DS: Regulation of the procoagulant activity within the bronchoalveolar compartment of normal human lung. Am Rev Respir Dis. 1988;137:1417-1425.
6. Idell S, Gonzalez KK, MacArthur CK, Gillies C, Walsh PN, McLarty J, Thrall RS: Bronchoalveolar lavage procoagulant activity in bleomycin-induced lung injury in marmosets. Characterization and relationship to fibrin deposition and fibrosis. Am Rev Respir Dis. 1987;136:124-133.
7. Idell S, James KK, Gillies C, Fair DS, Thrall RS: Abnormalities of pathways of librin turnover in lung lavage of rats with oleic acid and blcomycin-induced lung injury support alveolar deposition. Am J Pathol. 1989;135:387-399.
8. Olman MA, Mackman N, Gladson CL, Moser KM, Loskutoff DJ: Changes in procoagulant and fibrinolytic gene expression during blcomycin-induced lung injury in the mouse. J Clin Invest 1995;96:1621-1630.
9. Hendey B, Mamrack MD: Differential response of normal human fibroblasts to bombesin versus thrombin. J Cell Physiol. 1988;136:486-492.
10. Chen LB, Buchanan JM: Mitogenic activity of blood components. I. Thrombin and prothrombin. Proc Natl Acad Sci USA. 1975;72:131-135.
11. Tani K, Yasuoka S, Ogushi F, Asada K, Fujisawa K, Ozaki T, Sano N, Ogura T: Thrombin enhances lung fibroblast proliferation in Bleomycin-induced pulmonary fibrosis. Am J Respir Cell Mol Biol. 1991;5:34-40.
12. Weitz JI: Low-molecular-weight heparins. N Engl J Med. 1997;337:688-698.
13. Frizelle S, Schwartz J, Huber SA, Leslie K: Evaluation of the effects of low molecular weight heparin on inflammation and collagen deposition in chronic coxsackievirus B3-induced myocarditis in A/J mice. Am J Pathol. 1992;141:203-209.
14. Fantz M, Bertoli D: General pharmacological properties of the low molecular heparin in rodents. Drugs Res. 1986;9:1366-1368.
15. Lowry OH, Rosebrough NJ, Fair AL, Randall RJ: Protein measurement with the Falin phenol reagent. J Biol Chem. 1951;193:265-275.
16. Lossos IS, Or R, Goldstein RH, Breuer R: Amelioration of bleomycin-induced pulmonary injury by cyclosporin A. Exp Lung Res. 1996;22:337-349.
17. Snedecor GW, Cochran WG: Statistical Methods, 6th ed. Ames, TA: Iowa State University Press; 1967.
18. Schrier DJ, Phan SH, McGarry BM: The effects of the nude (nu/nu) mutation on bleomycin-induced pulmonary fibrosis. A biochemical evaluation. Am Rev Respir Dis. 1983;127:614-617.
19. Schrier DJ, Phan SH: Modulation of bleomycin-induced pulmonary fibrosis in the BALB/c mouse by cyclophosphamide-sensitive T cells. Am J Pathol. 1984;116:270-278.
20. Belw M, Gerdin B, Porath J, Saldeen T: Isolation of vasoactive peptides from human fibrin and fibrinogen degraded by plasmin. Thromb Res. 1978;13:983-994.
21. Skogen WF, Senior RM, Griffin GL, Wilner GD: Fibrinogen-derived peptide Bβ1-42 is a multi-domained neutrophil chemoattractant. Blood 1988;71:145-149.
22. Senior RM, Skogen WF, Griffin GL, Wilner GD: Effects of fibrinogen derivatives upon the inflammatory response: studies with human fibrinopeptide B. J Clin Invest. 1986;77:1014-1019.
23. Bunce LA, Sporn LA, Francis CW: Endothelial cell spreading on fibrin requires fibrinopeptide B cleavage and amino acid residues 15-42 of the β chain. J Clin Invest. 1992;89:842-850.
24. McGee MP, Rothberger H: Tissue factor in bronchoalvcolar lavage fluids. Am Rev Respir Dis. 1985;131:331-336.
25. Eitzman DT, McCoy RD, Zheng X, Fay WP, Shen T, Ginsburg D, Simon RH. Bleomycin-induced pulmonary fibrosis in transgenic mice that either lack or overexpress the murine plasminogen activator inhibitor gene. J Clin Invest. 1996;97:232-237.
26. 1 secreted by rat alveolar macrophages after in vivo bleomycin injury. Am J Respir Cell Mol Biol. 1996;15:252-259.
27. Giri SN, Hyde DM, Hollinger MA: Effect of antibody to transforming growth factor β on bleomycin induced accumulation of lung collagen in mice. Thorax. 1993;48:959-966.
28. Sandset PM, Abildgaard U, Larsen ML: Heparin induces release of extrinsic coagulation pathway inhibitor (EPI). Thromb Res. 1988;50:803-813.
29. Broze GL Jr. Tissue factor pathway inhibitor. Thromb Haemostas. 1995;74:90-93.
30. Nelson RM, Cecconi O, Roberts WG, Aruffo A, Linharat RJ; Bevilacqua MP: Heparin oligosaccharides bind L- and P-selectin and inhibit acute inflammation. Blood 1993;82:3253-3258.
31. Matzner Y, Marx G, Drexler R, Eldor A: The inhibiting effect of heparin and related glycosaminoglycans on neutrophil chemotaxis. Thromb Haemostas. 1984;52:134-137.
32. Dziarski R. Enhancement of mixed leukocyte reaction and cytotoxic antitumor response by heparin. J Immunol. 1989;143:356-365.
33. Piguet PF, Van GY, Guo J: Heparin attenuates bleomycin but not silica-induced pulmonary fibrosis in mice: possible relationship with involvement of myofibroblasts in bleomycin, and fibroblasts in silica-induced fibrosis. Int J Exp Pathol. 1996;77:155-161.